

# Clinical trials of vorapaxar

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 post myocardial infarction

Trial	Treatments	Patients	Trials design and methods
<b>vorapaxar vs placebo (on top aspirin)</b>			
<a href="#">TRA-2P TIMI 50 , 2012</a> [NCT00526474] n=13225/13244 follow-up: 2.5 y (median)	vorapaxar (SCH 530348) 2.5-mg daily versus placebo (added to the existing standard of care for preventing heart attack and stroke (eg, aspirin, clopidogrel)	patients with a known history of atherosclerosis (MI, ischemic stroke, or peripheral vascular disease)	Parallel groups double-blind

More details and results :

- antiplatelets drug for post myocardial infarction in all type of patient at <http://www.trialresultscenter.org/go-Q277>

## References

### TRA-2P TIMI 50, 2012:

Morrow DA, Scirica BM, Fox KA, Berman G, Strony J, Veltri E, Bonaca MP, Fish P, McCabe CH, Braunwald E Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. Am Heart J 2009 Sep;158:335-341.e3 [[19699854](#)]

Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KA, Lipka LJ, Liu X, Nicolau JC, Oude Ophuis AJ, Paolasso E, Scirica BM, Spinar J, Theroux P, Wiviott SD, Strony J, Murphy SA Vorapaxar in the Secondary Prevention of Atherothrombotic Events. N Engl J Med 2012 Mar 24;: [[22443427](#)]  
[10.1056/NEJMoa1200933](#)

Scirica BM, Bonaca MP, Braunwald E, De Ferrari GM, Isaza D, Lewis BS, Mehrhof F, Merlini PA, Murphy SA, Sabatine MS, Tendera M, Van de Werf F, Wilcox R, Morrow DA Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2P-TIMI 50 trial. Lancet 2012;380:1317-24 [[22932716](#)]

## 2 cardiovascular prevention

Trial	Treatments	Patients	Trials design and methods
<b>vorapaxar vs placebo (on top aspirin)</b>			

continued...

<b>Trial</b>	<b>Treatments</b>	<b>Patients</b>	<b>Trials design and methods</b>
TRA-2P TIMI 50 , 2012 [NCT00526474] n=13225/13244 follow-up: 2.5 y (median)	vorapaxar (SCH 530348) 2.5-mg daily versus placebo (added to the existing standard of care for preventing heart attack and stroke (eg, aspirin, clopidogrel)	patients with a known history of atherosclerosis (MI, ischemic stroke, or peripheral vascular disease)	Parallel groups double-blind
TRA-2P TIMI 50 (no prior stroke sub group) , 2012 n=20699 follow-up: 2.5 y (median)	vorapaxar (SCH 530348) 2.5-mg daily versus placebo (added to the existing standard of care for preventing heart attack and stroke (eg, aspirin, clopidogrel)	patients with a known history of atherosclerosis (MI, ischemic stroke, or peripheral vascular disease), sub group of patient with no prior stroke	Parallel groups double-blind
TRA-2P TIMI 50 (MI subgroup) , 2012 [NCT00526474] n=8898/8881 follow-up: 2.5 y (median)	vorapaxar (SCH 530348) 2.5-mg daily versus placebo (added to the existing standard of care for preventing heart attack and stroke (eg, aspirin, clopidogrel)	prespecified subgroup of patients with a qualifying myocardial infarction among the overall population of patients with a known history of atherosclerosis (MI, ischemic stroke, or peripheral vascular disease)	Parallel groups double-blind multinational

More details and results :

- antithrombotics for cardiovascular prevention in all type of patients at <http://www.trialresultscenter.org/go-Q132>
- antiplatelets drug for cardiovascular prevention in all type of patients at <http://www.trialresultscenter.org/go-Q226>
- antiplatelets drug for cardiovascular prevention in secondary prevention in patients with intermittent claudication at <http://www.trialresultscenter.org/go-Q275>
- antiplatelets drug for cardiovascular prevention in secondary prevention in patients with CAD at <http://www.trialresultscenter.org/go-Q276>
- antithrombotics for cardiovascular prevention in secondary prevention at <http://www.trialresultscenter.org/go-Q663>

## References

### TRA-2P TIMI 50, 2012:

Morrow DA, Scirica BM, Fox KA, Berman G, Strony J, Veltri E, Bonaca MP, Fish P, McCabe CH, Braunwald E Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. Am Heart J 2009 Sep;158:335-341.e3 [19699854]

Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KA, Lipka LJ, Liu X, Nicolau JC, Oude Ophuis AJ, Paolasso E, Scirica BM, Spinar J, Theroux P, Wiviott SD, Strony J, Murphy SA Vorapaxar in the Secondary Prevention of Atherothrombotic Events. N Engl J Med 2012 Mar 24;: [22443427] [10.1056/NEJMoa1200933](https://doi.org/10.1056/NEJMoa1200933)

Scirica BM, Bonaca MP, Braunwald E, De Ferrari GM, Isaza D, Lewis BS, Mehrhof F, Merlini PA, Murphy SA, Sabatine MS, Tendera M, Van de Werf F, Wilcox R, Morrow DA Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2P-TIMI 50 trial. Lancet 2012;380:1317-24 [22932716]

#### **TRA-2P TIMI 50 (no prior stroke sub group), 2012:**

Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KA, Lipka LJ, Liu X, Nicolau JC, Oude Ophuis AJ, Paolasso E, Scirica BM, Spinar J, Theroux P, Wiviott SD, Strony J, Murphy SA Vorapaxar in the Secondary Prevention of Atherothrombotic Events. N Engl J Med 2012 Mar 24;: [22443427] [10.1056/NEJMoa1200933](https://doi.org/10.1056/NEJMoa1200933)

#### **TRA-2P TIMI 50 (MI subgroup), 2012:**

Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KA, Lipka LJ, Liu X, Nicolau JC, Oude Ophuis AJ, Paolasso E, Scirica BM, Spinar J, Theroux P, Wiviott SD, Strony J, Murphy SA Vorapaxar in the Secondary Prevention of Atherothrombotic Events. N Engl J Med 2012 Mar 24;: [22443427] [10.1056/NEJMoa1200933](https://doi.org/10.1056/NEJMoa1200933)

Scirica BM, Bonaca MP, Braunwald E, De Ferrari GM, Isaza D, Lewis BS, Mehrhof F, Merlini PA, Murphy SA, Sabatine MS, Tendera M, Van de Werf F, Wilcox R, Morrow DA Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2P-TIMI 50 trial. Lancet 2012 Aug 24;: [22932716] [10.1016/S0140-6736\(12\)61269-0](https://doi.org/10.1016/S0140-6736(12)61269-0)

3

### **3 acute coronary syndrome**

<b>Trial</b>	<b>Treatments</b>	<b>Patients</b>	<b>Trials design and methods</b>
<b>vorapaxar vs placebo (on top standard therapy)</b>			
<b>TRACER , 2011</b> [NCT00527943] n=NA follow-up:	vorapaxar (SCH 530348) oral tablets; 40-mg loading dose on first day, followed by 2.5 mg once daily for at least 1 year versus Placebo (added to the existing standard of care (eg, aspirin, clopidogrel)	patients with acute coronary syndrome	Parallel groups double-blind

More details and results :

- antithrombotics for acute coronary syndrome in all type of patients at <http://www.trialresultscenter.org/go-Q24>
- antiplatelets drug for acute coronary syndrome in all type of patients at <http://www.trialresultscenter.org/go-Q346>

### **References**

**TRACER, 2011:**

The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA\*CER) trial: study design and rationale. *Am Heart J* 2009 Sep;158:327-334.e4 [[19699853](#)]

Tricoci P, Huang Z, Held C, Moliterno DJ, Armstrong PW, Van de Werf F, White HD, Aylward PE, Wallentin L, Chen E, Lokhnygina Y, Pei J, Leonardi S, Rorick TL, Kilian AM, Jennings LH, Ambrosio G, Bode C, Cequier A, Cornel JH, Diaz R, Erkan A, Huber K, Hudso Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes. *N Engl J Med* 2011 Nov 13;: [[22077816](#)] [10.1056/NEJMoa1109719](#)

Entry terms: Zontivity, SCH 530348, SCH530348, SCH-530348,